Therapeutic Potential for Caspase Inhibitors Present and Future

Design of Caspase Inhibitors as Potential Clinical Agents

Volumn , Issue , 2008, Pages 251-288

  Eda, Hiroyuki ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85133990256     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9781420045413-14     Document Type: Chapter

References (241)

1. Dinarello, C. A. 1996. Biological basis for interleukin-1 in disease. Blood 87:2095.
2. H1-inducing, proinflammatory cytokine and new member of the IL-1 family. J. Allergy Clin. Immunol. 103:11.
3. Kim, T. W., et al. 1997. Alternative cleavage of Alzheimer-associated presenilins during apoptosis by a caspase-3 family protease. Science 277:373.
4. Barnes, N. Y., et al. 1998. Increased production of amyloid precursor protein provides a substrate for caspase-3 in dying motoneurons. J. Neurosci. 18:5869.
5. Walter, J., et al. 1999. Phosphorylation of presenilin-2 regulates its cleavage by caspases and regards progression of apoptosis. Proc. Natl. Acad. Sci. USA 96:1391.
6. Hartmann, A., et al. 2000. Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson’s disease. Proc. Natl. Acad. Sci. USA 97:2875.
7. Hartmann, A., et al. 2001. Caspase-8 is an effector in apoptotic death of dopaminergic neurons in Parkinson’s disease, but pathway inhibition results in neuronal necrosis. J. Neurosci. 21:2247.
8. Yue, T. L., et al. 1998. Staurosporine-induced apoptosis in cardiomyocytes: A potential role of caspase-3. J. Mol. Cell Cardiol. 30:495.
9. Narula, J., et al. 1999. Apoptosis in heart failure: Release of cytochrome c from mitochondria and activation of caspase-3 in human cardiomyopathy. Proc. Natl. Acad. Sci. USA 96:8144.
10. Jaeschke, H., et al. 1998. Activation of caspase 3 (CPP32)-like proteases is essential for TNF-alpha-induced hepatic parenchymal cell apoptosis and neutrophil-mediated necrosis in a murine endotoxin shock model. J. Immunol. 160:3480.
11. Tinsley, K. W., et al. 2000. Caspases -2, -3, -6, and -9, but not caspase-1, are activated in sepsis-induced thymocyte apoptosis. Shock 13:1.
12. Patel, T., Bronk, S. F., and Gores, G. J. 1994. Increases of intracellular magnesium promote glycodeoxycholate-induced apoptosis in rat hepatocytes. J. Clin. Invest. 94:2183.
13. Que, F. Q., and Gores, G. J. 1996. Cell death by apoptosis: Basic concepts and disease relevance for the gastroenterologist. Gastroenterology 110:1238.
14. Sasaki, H., et al. 1996. Activation of apoptosis during the reperfusion phase after rat liver ischemia. Transplant. Proc. 28:1908.
15. Borghi-Scoazec, G., et al. 1997. Apoptosis after ischemia-reperfusion in human liver allografts. Liver Transplant. Surg. 3:407.
16. Kuo, P. C., et al. 1998. Apoptosis and hepatic allograft reperfusion injury. Clin. Transplant. 12:219.
17. Schuchmann, M., and Galle, P. R. 2001. Apoptosis in liver disease. Eur. J. Gastroenterol. Hepatol. 13:785.
18. Natori, S., et al. 2001. Hepatocyte apoptosis is a pathologic feature of human alcoholic hepatitis. J. Hepatol. 34:248.
19. Ziol, M., et al. 2001. Clinical and biological relevance of hepatocyte apoptosis in alcoholic hepatitis. J. Hepatol. 34:254.
20. Bantel, H., et al. 2001. Caspase activation correlates with the degree of inflammatory liver injury in chronic hepatitis C virus infection. Hepatology 34:758.
21. Bantel, H., and Schulze-Osthoff, K. 2003. Apoptosis in hepatitis C virus infection. Cell Death Differ. 10:S48.
22. Kountouras, J., Zavos, C., and Chatzopoulos, D. 2003. Apoptosis in hepatitis C. J. Viral. Hepatol. 10:335.
23. Feldstein, A. E., et al. 2003. Hepatocyte apoptosis and Fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 125:437.
24. Ribeiro, P. S., et al. 2004. Hepatocyte apoptosis, expression of death receptors, and activation of NF-κB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am. J. Gastroenterol. 99:1708.
25. Abrahamson, E. E., et al. 2006. Caspase inhibition therapy abolishes brain trauma-induced increases in Abeta peptide: Implications for clinical outcome. Exp. Neurol. 197:437.
26. Yang, L., et al. 2004. A novel systemically active caspase inhibitor attenuates the toxicities of MPTP, malonate, and 3NP in vivo. Neurobiol. Dis. 17:250.
27. Neviere, R., et al. 2001. Caspase inhibition prevents cardiac dysfunction and heart apoptosis in a rat model of sepsis. Am. J. Respir. Crit. Care Med. 163:218.
28. Hayakawa, Y., et al. 2003. Inhibition of cardiac myocyte apoptosis improves cardiac function and abolishes mortality in the peripartum cardiomyopathy of Gαq transgenic mice. Circulation 108:3036.
29. Hotchkiss, R. S., et al. 1999. Prevention of lymphocyte cell death in sepsis improves survival in mice. Proc. Natl. Acad. Sci. USA 96:14541.
30. Schulz, J. B., Weller, M., and Moskowitz, M. A. 1999. Caspases as treatment targets in stroke and neurodegenerative diseases. Ann. Neurol. 45:421.
31. Braun, J. S., Tuomanen, E. I., and Cleveland, J. L. 1999. Neuroprotection by caspase inhibitors. Expert Opin. Invest. Drugs 8:1599.
32. Sastry, P. S., and Rao, K. S. 2000. Apoptosis and the nervous system. J. Neurochem. 74:1.
33. Jaeschke, H., et al. 2000. Protection against TNF-induced liver parenchymal cell apoptosis during endotoxemia by a novel caspase inhibitor in mice. Toxicol. Appl. Pharmacol. 169:77.
34. Kim, K. M., et al. 2000. A broad-spectrum caspase inhibitor blocks concanavalin A-induced hepatitis in mice. Clin. Immunol. 97:221.
35. Yang, W., et al. 2003. MX1013, a dipeptide caspase inhibitor with potent in vivo antiapoptotic activity. Br. J. Pharmacol. 140:402.
36. Natori, S., et al. 2003. The caspase inhibitor IDN-6556 prevents caspase activation and apoptosis in sunisoidal endothelial cells during liver preservation injury. Liver Transplant. 9:278.
37. Niel, C., et al. 2003. Characterization of IDN-6556 (3-{2-(2-tert-butyl-phenylaminooxalyl)-amino]-propionylamino}-4-oxo-5-(2, 3, 5, 6-tetrafluoro-phenyl)-pentanoic acid): A liver-targeted caspase inhibitor. J. Pharmacol. Exp. Ther. 309:634.
38. Canbay, A., et al. 2004. The caspase inhibitor IDN-6556 attenuates hepatic injury and fibrosis in the bile duct ligated mouse. J. Pharmacol. Exp. Ther. 308:1191.
39. Baskin-Bey, E. S., et al. 2006. The pan-caspase inhibitor, IDN-6556, attenuates human liver preservation injury. Hepatology 44(Suppl. 1):190A.
40. Shiffman, M. L., et al. 2006. PF-03491390 (formerly IDN-6556), a pancaspase inhibitor, is well-tolerated and effectively reduces raised aminotransferases (ALT and AST) in chronic active hepatitis C (HCV) patients (PTS). Hepatology 44(Suppl. 1):224A.
41. Li, P., et al. 1995. Mice deficient in IL-1 beta-converting enzyme are defective in production of mature IL-1 beta and resistant to endotoxic shock. Cell 80:401.
42. Kuida, K., et al. 1995. Altered cytokine export and apoptosis in mice deficient in interleukin-1 beta converting enzyme. Science 267:2000.
43. Siegmund, B., and Zeits, M. 2003. Pralnacasan Vertex Pharmaceuticals. Idrugs 6:154.
44. Ku, G., et al. 2001. Selective interleukin-1β converting enzyme (ICE/Caspase-1) inhibition with pralnacasan (HMR 3480/VX-740) reduces inflammation and joint destruction in murine type II collagen-induced arthritis (CIA). Arthritis Rheum. 44: S241.
45. Rudolphi, K., et al. 2003. Pralnacasan, an inhibitor of interleukin-1 beta converting enzyme, reduces joint damage in two murine models of osteoarthritis. Osteoarthritis Cartilage 11:738.
46. Loher, F., et al. 2004. The interleukin-1 beta converting enzyme inhibitor pralnacasan reduces dextran sulfate sodium-induced murine colitis and T helper 1 T-cell activation. J. Pharmacol. Exp. Ther. 308:583.
47. Pavelka, K., et al. 2002. Clinical effects of pralnacasan (PRAL), an orally-active interleukin-1 beta converting enzyme (ICE) inhibitor, in a 285 patient PhII trial in rheumatoid arthritis (RA). In 66th Annual Science Meeting of the American College of Rheumatology, abstract LB02.
48. Fischer, U., and Schulze-Osthoff, K. 2005. Apoptosis-based therapies and drug targets. Cell Death Differ. 12:942.
49. Randle, J., Ku, G., and Qadri, A. 2001. Interleukin-1b converting enzyme (caspase-1) inhibition with VX-765 reduces inflammation and cytokine levels in murine oxazolone-induced dermatitis. J. Invest. Dermatol. 117:532.
50. Braddock, M. 2003. Inflammatory process in drug discovery-SRI conference. IDrugs 6:1049.
51. Braddock, M., and Quinn, A. 2004. Targeting IL-1 in inflammatory disease: New opportunities for therapeutic intervention. Nat. Rev. Drug Discovery 3:1.
52. Le, G. T., and Abbenante, G. 2005. Inhibitors of TACE and caspase-1 as anti-inflammatory drugs. Curr. Med. Chem. 12: 2963.
53. Stack, J. H., et al. 2005. IL-converting enzyme/caspase-1 inhibitor VX-765 blocks the hypersensitive response to an inflammatory stimulus in monocytes from familial cold autoinflammatory syndrome patients. J. Immunol. 175:2630.
54. Faubel, S., and Edelstein, C. L. 2005. Caspases as drug targets in ischemic organ injury. Curr. Drug Targets Immune Endocr. Metabol. Disord. 5:269.
55. Siegmund, B., et al. 2001. IL-1b-converting enzyme (caspase-1) in intestinal inflammation. Proc. Natl. Acad. Sci. USA 98:13249.
56. Schielke, G. P., et al. 1998. Reduced ischemic brain injury in interleukin-1 beta converting enzyme-deficient mice. J. Cereb. Blood Flow Metab. 18:180.
57. Ona, V. O., et al. 1999. Inhibition of caspase-1 slows disease progression in a mouse model of Huntinton’s disease. Nature 399:263.
58. Rodriguez, I., et al. 1996. Systemic injection of tripeptide inhibits the intracellular activation of CPP-32-like proteases in vivo and fully protects mice against Fas-mediated fulminant liver destruction and death. J. Exp. Med. 184:2067.
59. Hiramatsu, N., et al. 1994. Immunohistochemical detection of Fas antigen in liver tissue of patients with chronic hepatitis C. Hepatology 19:1354.
60. Mita, E., et al. 1994. Role of Fas ligand in apoptosis induced by hepatitis C virus infection. Biochem. Biophys. Res. Commun. 204:468.
61. Okazaki, M., et al. 1996. Hepatic Fas antigen expression before and after interferon therapy in patients with chronic hepatitis C. Dig. Dis. Sci. 41:2453.
62. Ando, K., et al. 1994. Class I-restricted cytotoxic T lymphocytes are directly cytopathic for their target cells in vivo. J. Immunol. 152:3245.
63. Kondo, T., et al. 1997. Essential roles of the Fas ligand in the development of hepatitis. Nature Med. 3:409.
64. Iio, S., et al. 1998. Serum levels of soluble Fas antigen in chronic hepatitis C patients. J. Hepatol. 29:517.
65. Pianko, S., et al. 2001. Fas-mediated hepatocyte apoptosis is increased by hepatitis C virus infection and alcohol consumption, and may be associated with hepatic fibrosis: Mechanism of liver injury in chronic hepatitis C virus infection. J. Viral Hepat. 8:406.
66. Bantel, H., et al. 2001. Caspase activation correlates with the degree of inflammatory liver injury in chronic hepatitis C virus infection. Hepatology 34:758.
67. Jaeschke, H., et al. 1998. Activation of caspase 3 (CPP-32)-like proteases is essential for TNF-alpha-induced hepatic parenchymal cell apoptosis and neutrophil-mediated necrosis in a murine endotoxin shock model. J. Immunol. 160:3480.
68. Lawson, J. A., et al. 1998. Parenchymal cell apoptosis as a signal for sinusoidal sequesteration and transendothelial migration of neutrophils in murine models of endotoxin and Fas-antibody-induced liver injury. Hepatology 28:865.
69. Bantel, H., et al. 2004. Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury. Hepatology 40:1078.
70. Faubion, W. A., et al. 1999. Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas. J. Clin. Invest. 103:137.
71. Higuchi, H., et al. 2002. Cholestasis increases tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-R2/DR5 expression and sensitizes the liver to TRAILmediated cytotoxicity. J. Pharmacol. Exp. Ther. 303:461.
72. Higuchi, H., et al. 2003. Bile acids stimulate cFLIP phosphorylation enhancing TRAIL-mediated apoptosis. J. Biol. Chem. 278:454.
73. Goldin, R. D., et al. 1993. Apoptotic bodies in a murine model of alcoholic liver disease: Reversibility of ethanol-induced changes. J. Pathol. 171:73.
74. Yacoub, L. K., et al. 1995. Apoptotic and bcl-2 protein expression in experimental alcoholic liver disease in the rat. Alcohol Clin. Exp. Res. 19:854.
75. Castilla, R., et al. 2004. Dual effect of ethanol on cell death in primary culture of human and rat hepatocytes. Alcohol Alcoholism 39:290.
76. Arteel, G. E. 2003. Oxidants and antioxidants in alcohol-induced liver disease. Gastroenterology 124:778.
77. Thurman, R. G. 1998. Mechanisms of hepatic toxicity. II. Alcoholic liver injury involves activation of Kupffer cells by endotoxin. Am. J. Physiol. 275:G605.
78. Uesugi, T., et al. 2001. Toll-like receptor 4 is involved in the mechanism of early alcohol-induced liver injury in mice. Hepatology 34:101.
79. Kono, H., et al. 2000. NADPH oxidase-derived free radicals are key oxidants in alcohol-induced liver disease. J. Clin. Invest. 106:867.
80. Yin, M., et al. 1999. Essential role of tumor necrosis factor a in alcohol-induced liver injury in mice. Gastroenterology 117:942.
81. Morimoto, M., et al. 1993. Role of cytochrome P4502E1 in alcoholic liver disease pathogenesis. Alcohol 10:459.
82. Morimoto, M., et al. 1995. Modulation of experimental alcohol-induced liver disease by cytochrome P450 2E1 inhibitors. Hepatology 21:1610.
83. Morgan, K., French, S. W., and Morgan, T. R. 2002. Production of a cytochrome P450 2E1 transgenic mouse and initial evaluation of alcoholic liver damage. Hepatology 36:122.
84. Kono, H. et al. 1999. CYP2E1 is not involved in early alcohol-induced liver injury. Am. J. Physiol. 277:G1259.
85. Dey, A., and Cederbaum, A. I. 2006. Alcohol and oxidative liver injury. Hepatology 43:S63.
86. Farrell, G. C. 2003. Non-alcoholic steatohepatitis: What is it, and why is it important in the Asia-Pacific region? J. Gastroenterol. Hepatol. 18:124.
87. Clark, J. M., Brancati, F. L., and Diehl, A. M. 2003. The prevalence and etiology of elevated aminotransferase levels in the United States. Am. J. Gastroenterol. 98:960.
88. McCullough, A. J. 2006. Pathophysiology of nonalcoholic steatohepatitis. J. Clin. Gastroenterol. 40:S17.
89. Ludwig, J., et al. 1980. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin. Proc. 55:434.
90. Day, C. P., and James, O. F. W. 1998. Steatohepatitis: A tale of two “hits”? Gastroenterology 114:842.
91. Shepherd, R., and Kahn, B. B. 1999. Glucose transporters and insulin action. N. Engl. J. Med. 341:248.
92. Chitturi, A., et al. 2002. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 35:373.
93. Cohen, P., et al. 2002. Role of stearoyl-CoA desaturase-1 in leptin-mediated weight loss. Science 279:240.
94. Matsusue, K., et al. 2003. Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. J. Clin. Invest. 111:737.
95. Pessayre, D., Fromenty, B., and Mansouri, A. 2004. Mitochondrial injury in steatohepatitis. Eur. J. Gastroenterol. Hepatol. 16:1095.
96. Berson, A., et al. 1998. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology 114:764.
97. Sanyal, A. J., et al. 2001. Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities. Gastroenterology 120:1183.
98. Chalasani, N., et al. 2004. Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. Am. J. Gastroenterol. 99:1497.
99. Passayre, D., and Fromenty, B. 2005. NASH: A mitochondrial disease. J. Hepatol. 42:928.
100. Weltman, M. D., et al. 1998. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 27:128.
101. Brun, P., et al. 2007. Increased intestinal permeability in obese mice: New evidences in the pathogenesis of nonalcoholic steatohepatitis. Am. J. Physiol. Gastrointest. Liver Physiol. 292:G518.
102. Crespo, J., et al. 2001. Gene expression of tumor necrosis factor a and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 34:1158.
103. Hui, J. M., et al. 2004. Beyond insulin resistance in NASH: TNF-a or adiponectin? Hepatology 40:46.
104. Kirkland, R. A., et al. 2002. A Bax-induced pro-oxidant state is critical for cytochrome c release during programmed neuronal death. J. Neurosci. 22:6480.
105. Gao, W., et al. 1998. Apoptosis of sinusoidal endothelial cells is a critical mechanism of preservation injury in rat liver transplantation. Hepatology 27:1652.
106. Kohli, V., et al. 1999. Endothelial cell and hepatocyte deaths occur by apoptosis after ischemia-reperfusion injury in the rat liver. Transplantation 67:1099.
107. Natori, S., et al. 1999. Apoptosis of sinusoidal endothelial cells occurs during liver preservation injury by a caspase-dependent mechanism. Transplantation 68:89.
108. Caldwell-Kentel, J. C., et al. 1991. Kupffer cell activation and endothelial cell damage after storage of rat livers: Effects of reperfusion. Hepatology 13:83.
109. Sndram, D., et al. 2001. Synergism between platelets and leukocytes in inducing endothelial cell apoptosis in the cold ischemic rat liver: Kupffer cell-mediated injury. FASEB J. 15:1230.
110. Cursio, R., et al. 1999. A caspase inhibitor fully protects rats against lethal normothermic liver ischemia by inhibition of liver apoptosis. FASEB J. 13:253.
111. Jaeschke, H., and Lemasters, J. J. 2003. Apoptosis versus oncotic necrosis in hepatic ischemia/reperfusion injury. Gastroenterology 125:1246.
112. Gujal, J. S., et al. 2001. Mechanism of cell death during warm hepatic ischemiareperfusion in rats: Apoptosis or necrosis? Hepatology 33:397.
113. Friedman, S. L. 2003. Liver fibrosis-From bench to bedside. J. Hepatol. 38:S38.
114. Bataller, R., and Brenner, D. A. 2005. Liver fibrosis. J. Clin. Invest. 115:209.
115. Canbay, A., et al. 2003. Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab. Invest. 83:655.
116. Zhan, S. S., et al. 2006. Phagocytosis of apoptotic bodies by hepatic stellate cells induces NADHP oxidase and is associated with liver fibrosis in vivo. Hepatology 43:435.
117. Syed, M., et al. 2005. Caspase inhibition improves ischemia-reperfusion injury after lung transplantation. Am. J. Transplant. 5:292.
118. Miyoshi, H., et al. 1999. Hepatocyte apoptosis after bile duct ligation in the mouse involves Fas. Gastroenterology 117:669.
119. Canbay, A., et al. 2002. Fas enhances fibrogenesis in the bile duct ligated mouse: A link between apoptosis and fibrosis. Gastroenterology 123:1323.
120. Hoglen, N. C., et al. 2003. IDN-6556, the first anti-apoptotic caspase inhibitor: Preclinical efficacy and safety. Hepatology 38(Suppl.1):579A.
121. Valentino, K. L., et al. 2003. First clinical trial of a novel caspase inhibitor: Antiapoptotic caspase inhibitor, IDN-6556, improves liver enzymes. Int. J. Clin. Pharmacol. Ther. 41:441.
122. Schiff, E. R., et al. 2004. Oral, IDN-656, an anti-apoptotic caspase inhibitor, lowers aminotransferases in HCV patients. J. Hepatol. 40(Suppl. 1):24.
123. Baskin-Bey, E. S., et al. 2007. Clinical trial of the pan-caspase inhibitor, IDN-6556, in human liver preservation injury. Am. J. Transplant. 7:218.
124. Leers, M. P., et al. 1999. Immunohistochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J. Pathol. 187:567.
125. Alvarado-Kristensson, M., et al. 2004. p38-MAPK signals survival by phosphorylation of caspase-8 and caspase-3 in human neutrophils. J. Exp. Med. 199:449.
126. Rossi, A. G., et al. 2006. Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis. Nature Med. 12:1056.
127. Riley, N. A., et al. 2006. Granulocyte apoptosis and macrophage clearance of apoptotic cells as targets for pharmacological intervention in inflammatory diseases. Anti-infl. Antiallergy Agents Med. Chem. 5:3.
128. Park, M., et al. 2004. LB84318, a novel and small-molecule caspase inhibitor, potently protects hepatic damage in mouse models of liver injury. J. Hepatol. 40(Suppl. 1): 147.
129. Park, M., et al. 2004. LB84318, a novel and small-molecule caspase inhibitor, potently protects hepatic damage in mouse models of liver injury. Hepatology 40(Suppl. 4):694A.
130. Chang, H. K., et al. 2004. Discovery of a novel caspase inhibitor and protection of liver damage in mouse models. In 228th ACS National Meeting, abstract 267.
131. Manns, M. P., et al. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomized trial. Lancet 358:958.
132. Fried, M. W., et al. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347:975.
133. Fried, M. W. 2002. Side effects of therapy of hepatitis C and their management. Hepatology 36:S237.
134. Wieckowska, A., et al. 2006. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 44:27.
135. Malhi, H., et al. 2006. Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis. J. Biol. Chem. 281:12093.
136. Jaeschke, H., Farhood, A., and Smith, C. W. 1990. Neutrophils contribute to ischemia/reperfusion injury in rat liver in vivo. FASEB J. 4:3355.
137. Jaeschke, H., et al. 1993. Functional inactivation of neutrophils with a Mac-1 (CD11b/CD18) monoclonal antibody protects against ischemia-reperfusion injury in rat liver. Hepatology 17:915.
138. Jaeschke, H. 2003. Molecular mechanisms of hepatic ischemia-reperfusion injury and preconditioning. Am. J. Physiol. Gastrointest. Liver Physiol. 284:G15.
139. Kobayashi, A., et al. 2001. Mac-1 (CD11b/CD18) and intercellular adhesion molecule-1 in ischemia-reperfusion injury of rat liver. Am. J. Physiol. Gastrointest. Liver Physiol. 281:G577.
140. Contreras, J. L., et al. 2004. Caspase-8 and caspase-3 small interfering RNA decreases ischemia/reperfusion injury to the liver in mice. Surgery 136:390.
141. Malhi, H., Gores, G. J., and Lemasters, J. J. 2006. Apoptosis and necrosis in the liver: A tale of two deaths? Hepatology 43:S31.
142. Norman, J., et al. 1997. Severity and mortality of experimental pancreatitis are dependent on interleukin-1 converting enzyme (ICE). J. Interferon Cytokine Res. 17:113.
143. Melnikov, V. Y., et al. 2001. Impaired IL-18 processing protects caspase-1-deficient mice from ischemic acute renal failure. J. Clin. Invest. 107:1145.
144. Xu, H., et al. 2001. Attenuation of hypoxia-ischemia-induced monocyte chemoattractant protein-1 expression in brain of neonatal mice deficient in interleukin-1 converting enzyme. Mol. Brain Res. 90:57.
145. Koedel, U., et al. 2002. Role of caspase-1 in experimental pneumococcal meningitis: Evidence from pharmacologic caspase inhibition and caspase-1-deficient mice. Ann. Neurol. 51:319.
146. Bröker, L. E., Kruyt, F. A. E., and Giaccone, G. 2005. Cell death independent of caspases: A review. Clin. Cancer Res. 11:3155.
147. Hetz, C. A., Torres, V., and Quest, A. F. G. 2005. Beyond apoptosis: Nonapoptotic cell death in physiology and disease. Biochem. Cell Biol. 83:579.
148. Kim, R., et al. 2006. Regulation and interplay of apoptotic and non-apoptotic cell death. J. Pathol. 208:319.
149. Kroemer, G., and Martin, S. J. 2005. Caspase-independent cell death. Nature Med. 11:725.
150. Hail, Jr., N., et al. 2006. Apoptosis effector mechanisms: A requiem performed in different keys. Apoptosis 11:889.
151. Vandenabeele, P., Berghe, T. V., and Festjens, N. 2006. Caspase inhibitors promote alternative cell death pathways. Science STKE, October 24, pe44.
152. Xiang, J., Chao, D. T., and Korsmeyer, S. J. 1996. BAX-induced cell death may not require interleukin 1β-converting enzyme-like proteases. Proc. Natl. Acad. Sci. USA 93:14559.
153. Pérez-Galán, P., et al. 2002. Role of caspases and apoptotic-inducing factor (AIF) in cladribine-induced apoptosis of B cell chronic lymphotic leukemia. Leukemia 16:2106.
154. Cauwels, A., et al. 2003. Caspase inhibition causes hyperacute tumor necrosis factorinduced shock via oxidative stress and phospholipase A2. Nature Immunol. 4:387.
155. Bidère, N., et al. 2003. Cathepsin D triggers Bax activation, resulting in selective apoptosis-inducing factor (AIF) relocation in T lymphocytes entering the early commitment phase to apoptosis. J. Biol. Chem. 278:31401.
156. Carter, B. Z., et al. 2003. Caspase-independent cell death in AML: Caspase inhibition in vitro with pan-caspase inhibitors or in vivo by XIAP or survivin does not affect cell survival or prognosis. Blood 102:4179.
157. Maianski, N. A., Roos, D., and Kuijpers, T. W. 2003. Tumor necrosis factor a induces a caspase-independent death pathway in human neutrophils. Blood 101:1987.
158. Konopleva, M., et al. 2004. The synthetic triterpenoid 2-cyano-3, 12-dioxooleana-1, 9-dien-28-oic acid induces caspase-dependent and -independent apoptosis in acute myelogenous leukemia. Cancer Res. 64:7927.
159. Kanzawa, T., et al. 2005. Arsenic trioxide induces autophagic cell death in malignant glioma cells by upregulation of mitochondrial cell death protein BNIP3. Oncogene 24:980.
160. Lum, J. J., et al. 2005. Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell 120:237.
161. Elmore, S. P., et al. 2001. The mitochondrial permeability transition initiates autophagy in rat hepatocytes. FASEB J. 15:2286.
162. MacDonald, G., et al. 1999. Mitochondria-dependent and -independent regulation of granzyme B-induced apoptosis. J. Exp. Med. 189:131.
163. Gozuacik, D., and Kimchi, A. 2004. Autophagy as a cell death and tumor suppressor mechanism. Oncogene 23:2891.
164. Kisen, G. O., et al. 1993. Reduced autophagic activity in primary rat hepatocellular carcinoma and ascites hepatoma cells. Carcinogenesis 14:2501.
165. Liang, X. H., et al. 1999. Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature 402:672.
166. Edinger, A. L., and Thompson, C. B. 2003. Defective autophagy leads to cancer. Cancer Cell 4:422.
167. Paglin, S., et al. 2001. A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles. Cancer Res. 61:439.
168. Degenhardt, K., et al. 2006. Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell 10:51.
169. Cuervo, A. M. 2004. Autophagy: In sickness and in health. Trends Cell Biol. 14:70.
170. Shintani, T., and Klionsky, D. J. 2004. Autophagy in health and disease: A doubleedged sword. Science 306:990.
171. Kondo, Y., et al. 2005. The role of autophagy in cancer development and response to therapy. Nat. Rev. Cancer 5:726.
172. Jin, S., and White, E. 2007. Role of autophagy in cancer. Autophagy 3:28.
173. Nakagawa, T., et al. 2000. Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-β. Nature 403:98.
174. Mathiasen, I. S., Lademann, U., and Jäättelä, M. 1999. Apoptosis induced by vitamin D compounds in breast cancer cells is inhibited by Bcl-2 but does not involve known caspase or p53. Cancer Res. 59:4898.
175. Mathiasen, I. S., et al. 2002. Calcium and calpain as key mediators of apoptosislike death induced by vitamin D compounds in breast cancer cells. J. Biol.Chem. 277:30738.
176. Lorenzo, H. K., and Susin, S. A. 2004. Mitochondrial effectors in caspase-independent cell death. FEBS Lett. 557:14.
177. Kim, R., Emi, M., and Tanabe, K. 2006. Role of mitochondria as the gardens of cell death. Cancer Chemother. Pharmacol. 57:545.
178. Susin, S. A., et al. 1996. Bcl-2 inhibits the mitochondrial release of an apoptogenic protease. J. Exp. Med. 184:1331.
179. Susin, S. A., et al. 1999. Molecular characterization of mitochondrial apoptosisinducing factor. Nature 397:441.
180. Suzuki, Y., et al. 2001. A serine protease, HtrA2, is released from the mitochondria and interacts with XIAP, inducing cell death. Mol. Cell. 8:613.
181. Hegde, R., et al. 2002. Identification of Omi/HtrA2 as a mitochondrial apoptotic serine protease that disrupts inhibitor of apoptosis protein-caspase interaction. J. Biol. Chem. 277:432.
182. Li, L. Y., and Wang, X. 2001. Endonuclease G is an apoptotic DNase when released from mitochondria. Nature 412:95.
183. Vercammen, D., et al. 1998. Inhibition of caspases increases the sensitivity of L929 calls to necrosis mediated by tumor necrosis factor. J. Exp. Med. 187:1477.
184. Holler, N., et al. 2000. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nature Immunol. 1:489.
185. Denecker, G., et al. 2001. Death receptor-induced apoptotic and necrotic cell death: Differential role of caspases and mitochondria. Cell Death Differ. 8:829.
186. Lin, Y., et al. 2004. Tumor necrosis factor-induced nonapoptotic cell death requires receptor-interacting protein-mediated cellular reactive oxygen species accumulation. J. Biol. Chem. 279:10822.
187. Balkwill, F., and Mantovani, A. 2001. Inflammation and cancer: Back to Virchow? Lancet 357:539.
188. Coussens, L. M., and Werb, Z. 2002. Inflammation and cancer. Nature 420:860.
189. Lu, H., et al. 2006. Inflammation, a key event in cancer development. Mol. Cancer Res. 4:221.
190. Saijo, Y., et al. 2002. Proinflammatory cytokine IL-1β promotes tumor growth of Lewis lung carcinoma by induction of angiogenesis factors: In vivo analysis of tumor-stromal interaction. J. Immunol. 169:469.
191. Voronov, E., et al. 2003. IL-1 is required for tumor invasiveness and angiogenesis. Proc. Natl. Acad. Sci. USA 100:2645.
192. Jung, Y. J., et al. 2003. IL-1β-mediated up-regulation of HIF-1α via an NFκB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J. 17:2115.
193. Teitz, T., et al. 2000. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nature Med. 6:529.
194. Teitz, T., Lahti, J. M., and Kidd, V. J. 2001. Aggressive childhood neuroblastomas do not express caspase-8: An important component of programmed cell death. J. Mol. Med. 79:428.
195. Fulda, S., et al. 2001. Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene 20:5865.
196. Harada, K., et al. 2002. Deregulation of caspase-8 and 10 expression in pediatric tumors and cell lines. Cancer Res. 62:5897.
197. Zuzak, T. J., et al. 2002. Loss of caspase-8 mRNA expression is common in childhood primitive neuroectodermal brain tumour/medulloblastoma. Eur. J. Cancer 38:83.
198. Joseph, B., et al. 1999. Differences in expression of pro-caspases in small cell and non-small cell lung carcinoma. Biochem. Biophys. Res. Commun. 262:381.
199. Shivapurkar, N., et al. 2002. Differential inactivation of caspase-8 in lung cancers. Cancer Biol. Ther. 1:65.
200. Shivapurkar, N., et al. 2002. Loss of expression of death-inducing signaling complex (DISC) components in lung cancer cell lines and the influence of MYC amplification. Oncogene 21:8510.
201. Hopkins-Donaldson, S., et al. 2003. Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation. Cell Death Differ. 10:356.
202. Fulda, S., et al. 2006. Loss of caspase-8 expression does not correlate with MYCN amplification, aggressive disease, or progress in neuroblastoma. Cancer Res. 66:10016.
203. Ricci-Vitiani, L., et al. 2004. Absence of caspase 8 and high expression of PED protect primitive neural cells from cell death. J. Exp. Med. 200:1257.
204. Estrov, Z., et al. 1998. Caspase 2 and caspase 3 protein levels as predictors of survival in acute myelogenous leukemia. Blood 92:3090.
205. Campos, L., et al. 1999. Expression of apoptosis-controlling proteins in acute leukemia cells. Leuk. Lymphoma 33:499.
206. Prokop, A., et al. 2000. Relapse in childhood acute lymphoblastic leukemia is associated with a decrease of the Bax/Bcl-2 ratio and loss of spontaneous caspase-3 processing in vivo. Leukemia 14:1606.
207. Svingen, P. A., et al. 2000. Evaluation of Apaf-1 and procaspase-2, -3, -7, -8, and -9 as potential prognostic markers in acute leukemia. Blood 96:3922.
208. Oliver, L., et al. 2002. Assessment of caspase activity as a possible prognostic factor in acute myeloid leukemia. Br. J. Haematol. 118:434.
209. Kaufmann, S. H., and Gores, G. J. 2000. Apoptosis in cancer: Cause and cure. Bioessays 22:1007.
210. Zöring, M., et al. 2001. Apoptosis regulators and their role in tumorigenesis. Biochim. Biophys. Acta 1551:F1.
211. Zhivotovsky, B., and Orrenius, S. 2006. Carcinogenesis and apoptosis: Paradigms and paradoxes. Carcinogenesis 27:1939.
212. Schwerk, C., and Schulze-Osthoff, K. 2003. Non-apoptotic functions of caspases in cellular proliferation and differentiation. Biochem. Pharmacol. 66:1453.
213. Oliver, L., and Vallette, F. M. 2005. The role of caspases in cell death and differentiation. Drug Resistance Updates 8:163.
214. Siegel, R. M. 2006. Caspases at the crossroads of immune-cell life and death. Nature Rev. Immunol. 6:308.
215. Lamkanfi, M., et al. 2007. Caspases in cell survival, proliferation and differentiation. Cell Death Differ. 14:44.
216. Zermati, Y., et al. 2001. Caspase activation is required for terminal erythroid differentiation. J. Exp. Med. 193:247.
217. Carlile, G. W., Smith, D. H., and Wiedmann, M. 2004. Caspase-3 has a nonapoptotic function in erythroid maturation. Blood 103:4310.
218. Sordet, O., et al. 2002. Specific involvement of caspases in the differentiation of monocytes into macrophages. Blood 100:4446.
219. de Botton, S., et al. 2002. Platelet formation is the consequence of caspase activation within megakaryocytes. Blood 100:1310.
220. Kuida, K., et al. 1996. Decreased apoptosis in the brain and premature lethality in CPP-32-deficient mice. Nature 384:368.
221. Woo, M., et al. 1998. Essential contribution of caspase 3/CPP32 to apoptosis and its associated nuclear changes. Genes Dev. 12:806.
222. Zheng, T. S., et al. 1998. Caspase-3 controls both cytoplasmic and nuclear events associated with Fas-mediated apoptosis in vivo. Proc. Natl. Acad. Sci. USA 95:13618.
223. Woo, M., et al. 2003. Caspase-3 regulates cell cycle in B cells: A consequence of substrate specificity. Nature Immunol. 4:1016.
224. Kang, T. B., et al. 2004. Caspase-8 serves both apoptotic and nonapoptotic roles. J. Immunol. 173:2976.
225. Pellegrini, M., et al. 2005. FADD and caspase-8 are required for cytokine-induced proliferation of hemopoietic progenitor cells. Blood 106:1581.
226. Doerfler, P., et al. 2000. Caspase enzyme activity is not essential for apoptosis during thymocyte development. J. Immunol. 164:4071.
227. Zhang, J., et al. 2000. Spontaneous thymocyte apoptosis is regulated by a mitochondrion-mediated signaling pathway. J. Immunol. 165:2970.
228. Li, J., et al. 2005. Survival versus neglect: Redefining thymocyte subsets based on expression of NKG2D ligand(s) and MHC class I. Eur. J. Immunol. 35:439.
229. Villunger, A., et al. 2004. Negative selection of semimature CD4+HAS+ thymocytes requires the BH3-only protein Bim but is independent of death receptor signaling. Proc. Natl. Acad. Sci. USA 101:7052.
230. Alam, A., et al. 1999. Early activation of caspases during T lymphocyte stimulation results in selective substrate cleavage in nonapoptotic cells. J. Exp. Med. 190:1879.
231. Kennedy, N. J., et al. 1999. Caspase activation is required for T cell proliferation. J. Exp. Med. 190:1891.
232. Wang, J., et al. 1999. Inherited human caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II. Cell 98:47.
233. Chun, H. J., et al. 2002. Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency. Nature 419:395.
234. Worth, A., Thrasher, A. J., and Gaspar, H. B. 2006. Autoimmune lymphoproliferative syndrome: Molecular basis of disease and clinical phenotype. Br. J. Haematol. 133:124.
235. Zhu, S., et al. 2006. Genetic alterations in caspase-10 may be causative or protective in autoimmune lymphoproliferative syndrome. Hum. Genet. 119:284.
236. Salmena, L., et al. 2003. Essential role for caspase 8 in T-cell homeostasis and T-cellmediated immunity. Genes Dev. 17:883.
237. Salmena, L., and Haken, R. 2005. Caspase-8 deficiency in T cells leads to a lethal lymphoinfiltrative immune disorder. J. Exp. Med. 202:727.
238. Chaudhary, P. M., et al. 2000. Activation of the NF-κB pathway by caspase 8 and its homologs. Oncogene 19:4451.
239. Kreuz, S., et al. 2004. NFκB activation by Fas is mediated through FADD, caspase-8, and RIP and is inhibited by FLIP. J. Cell Biol. 166:369.
240. Lamkanfi, M., et al. 2005. A novel caspase-2 complex containing TRAF2 and RIP1. J. Biol. Chem. 280, 6923.
241. Su, H., et al. 2005. Requirement for caspase-8 in NF-κB activation by antigen receptor. Science 307:1465.